Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL8482977 | 1.00 | DNMT1 (0.37) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL9125279 | 0.98 | DNMT1 (0.36) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL207077 | 0.98 | DNMT1 (0.36) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL626502 | 0.97 | DNMT1 (0.35) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL8058737 | 0.94 | MAPT (0.35) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL5697804 | 0.94 | MAPT (0.38) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL6259658 | 0.90 | MAPT (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL3641977 | 0.90 | DNMT1 (0.31) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL16684529 | 0.89 | MAPT (0.40) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL17609997 | 0.89 | MAPT (0.37) | DNMT1TP53MAPTSTAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3739 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392779-A1 | A METHOD OF DETERMINING AN IMMUNOGENIC RESPONSE CHARACTERISTIC OF A CHEMICAL SUBSTANCE | Fida Biosystems ApS (DK) | 2024-07-03 | — | — | EP | claimed |
| US-12012574-B2 | Process for removing dry surface biofilm | WHITELEY CORPORATION PTY. LTD. (AU) | 2024-06-18 | — | — | US | claimed |
| US-20240189242-A1 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME | MODERNATX, INC. (US) | 2024-06-13 | — | — | US | claimed |
| WO-2024096378-A1 | METHOD FOR PURIFYING TGF-β3 PROTEIN | 주식회사 대웅제약 | 2024-05-10 | — | — | WO | claimed |
| WO-2024044147-A1 | METHODS FOR PURIFICATION OF IONIZABLE LIPIDS | MODERNATX, INC. (US) | 2024-02-29 | — | — | WO | claimed |
| US-20240016827-A1 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME | MODERNATX, INC. (US) | 2024-01-18 | — | — | US | claimed |
| US-20230384188-A1 | ROOM TEMPERATURE STABLE, DRY BIOLOGICAL TRANSPORT MEDIA | GENTEGRA, LLC | 2023-11-30 | — | — | US | claimed |
| WO-2023227505-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-11-30 | — | — | WO | claimed |
| US-20230293735-A1 | OXINE-CONTAINING CELL RADIOLABELLING AGENTS | KING S COLLEGE LONDON (GB) | 2023-09-21 | — | — | US | claimed |
| EP-4242298-A2 | NANOPARTICLE FORMULATIONS | Taiga Biotechnologies, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| US-20070054342-A1 | Luciferase detection assay system | REVVITY HEALTH SCIENCES B.V. (NL) | 2007-03-08 | — | — | US | claimed |
| WO-2006121331-A1 | USE OF AMMONIUM AND PHOSPHATE IONS FOR IMPROVING THE DETECTION OF LUCIFERASE | PERKINELMER LIFE AND ANALYTICAL SCIENCES B.V. (NL) | 2006-11-16 | — | — | WO | claimed |
| WO-2006076663-A2 | KITS AND IMPROVED COMPOSITIONS FOR TREATING LOWER URINARY TRACT | URIGEN, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| US-20060127477-A1 | Novel preparation and administration form comprising an acid-labile active compound | ALTANA PHARMA AG | 2006-06-15 | — | — | US | claimed |
| EP-1616562-A1 | NOVEL PREPARATION AND ADMINISTRATION FORM COMPRISING AN ACID-LABILE ACTIVE COMPOUND | ALTANA Pharma AG (DE) | 2006-01-18 | — | — | EP | claimed |
| US-20050214885-A1 | Method for detecting mild impaired glucose tolerance or insulin hyposecretion | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-09-29 | — | — | US | claimed |
| EP-1187601-B1 | NOVEL PREPARATION AND ADMINISTRATION FORM COMPRISING AN ACID-LABILE PROTON PUMP INHIBITOR | ALTANA PHARMA AG (DE) | 2005-07-27 | — | — | EP | claimed |
| EP-0999275-B1 | Deoxynucleoside kinase from insect cells for the synthesis of nucleoside monophosphates | ROCHE DIAGNOSTICS GMBH (DE) | 2005-01-19 | — | — | EP | claimed |
| US-20020182600-A1 | Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques | SMITH JACK V (US) | 2002-12-05 | — | — | US | claimed |
| EP-0571593-B1 | NEW NON IONIC IODIZED AGENTS FOR X-RAY CONTRASTING, METHOD FOR PREPARING THEM AND GALENICAL COMPOSITIONS CONTAINING THEM | INVEST JUSTESA IMAGEN S A CENT (ES) | 1996-10-30 | — | — | EP | claimed |